Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Short term Debt (2022 - 2023)

bioAffinity Technologies (BIAF) has disclosed Short term Debt for 2 consecutive years, with $42334.0 as the latest value for Q2 2023.

  • On a quarterly basis, Short term Debt changed N/A to $42334.0 in Q2 2023 year-over-year; TTM through Jun 2023 was $42334.0, a N/A change, with the full-year FY2022 number at $251746.0, changed N/A from a year prior.
  • Short term Debt was $42334.0 for Q2 2023 at bioAffinity Technologies, down from $168430.0 in the prior quarter.
  • In the past five years, Short term Debt ranged from a high of $500000.0 in Q3 2022 to a low of $42334.0 in Q2 2023.